Lexicon Pharmaceuticals
Lexicon Pharmaceuticals' revenue rose 60.2% to $50 million in fiscal 2025. Its operating margin was −98.2%, up from −634.2% a year earlier. Free cash flow was −$68 million. The diluted share count rose 13.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Lexicon Pharmaceuticals does
Lexicon Pharmaceuticals is a drug company with one approved product, INPEFA (sotagliflozin), a once-daily tablet approved in the U.S. in May 2023 to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure or with type 2 diabetes, chronic kidney disease and other risk factors. It is also developing sotagliflozin as a treatment for hypertrophic cardiomyopathy, a condition in which the heart muscle thickens, in a late-stage trial called SONATA-HCM.
It is also seeking approval of the same drug, under the name ZYNQUISTA, for type 1 diabetes. The FDA issued complete response letters, which are refusals to approve as submitted, in March 2019 and December 2024. A public hearing process on whether there are grounds to deny approval is still going on. The company may resubmit its application if data from an outside study supports it.
Its third focus is pilavapadin, a pill for neuropathic pain, which is nerve pain. It reported positive results from two mid-stage trials in diabetic nerve pain, and it is looking for outside collaborators for its next steps. It puts most of its resources into research and into selling INPEFA.
Its biggest risks, as it describes them
- Its drug programs may fail to finish development or to win approval.
- Clinical trials may not show that its drugs are safe and effective.
- The FDA process for approval is long and uncertain, as ZYNQUISTA's earlier rejections show.
- It may not build a sales force and marketing system strong enough to sell its drugs.
Income statement
Lexicon Pharmaceuticals lost money in fiscal 2025: a net loss of $50 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 87 | 138 | 170 | 238 | 96 |
| Debt incl. finance leases | 0 | 49 | 100 | 100 | 54 |
| Net debt (negative means net cash) | −87 | −90 | −70 | −138 | −42 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.4x | 1.1x | 0.7x | 0.5x |
| Interest coverage | −108.6x | −36.2x | −17.1x | −15.3x | −5.9x |
| Current ratio | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
| Quick ratio | 4.0x | 6.1x | 5.6x | 5.4x | 4.9x |
Cash flow
Projections
Project Lexicon Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Lexicon Pharmaceuticals says to expect
- SONATA-HCM study: topline results timing
Lexicon continues to expect topline results in the first quarter of 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $2.7 million of Lexicon Pharmaceuticals shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Raymond DebbaneDirector | Bought | 2,000 | $1.49 | $2,980 | Form 4 |
| Feb 23, 2026 | Raymond DebbaneDirector | Bought | 100,000 | $1.47 | $147,000 | Form 4 |
| Feb 20, 2026 | Raymond DebbaneDirector | Bought | 100,000 | $1.48 | $148,000 | Form 4 |
| Feb 19, 2026 | Raymond DebbaneDirector | Bought | 50,000 | $1.44 | $72,000 | Form 4 |
| Feb 18, 2026 | Raymond DebbaneDirector | Bought | 133,688 | $1.32 | $176,468 | Form 4 |
| Feb 17, 2026 | Raymond DebbaneDirector | Bought | 76,857 | $1.31 | $100,683 | Form 4 |
| Feb 13, 2026 | Raymond DebbaneDirector | Bought | 57,952 | $1.31 | $75,917 | Form 4 |
| Feb 2, 2026 | Artal Group S.A.Director, 10% owner | Bought | 1,538,462 | $1.30 | $2.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 5 of 9 | 4 of 9 |
| Rule of 40 | −12,719.4% | 1,903.0% | −76.0% |
| Altman Z'' | −25.27 | −20.51 | −33.00 |
| Accruals ratio | −7.2% | −8.2% | 7.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 9 | 5 of 9 | 4 of 9 |
Compare
Put Lexicon Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals | FY25 | 60.2% | −98.2% | −136.2% | −105.0% | — | 4 | |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| IM Cannabis | FY25 | 1.3% | −21.2% | 8.6% | −64.9% | — | — | Compare |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 79 | 92 | 63 | 322 | 24 | 0 | 0 | 1 | 31 | 50 |
| Revenue growth | −39.0% | 15.7% | −31.1% | 409.5% | −92.5% | −98.8% | −53.4% | 766.2% | 2,481.5% | 60.2% |
| Gross profit | 79 | 90 | 61 | 319 | 22 | 0 | 0 | 1 | 30 | 50 |
| Research and development | 164 | 152 | 100 | 92 | 154 | 55 | 53 | 59 | 84 | 61 |
| Operating income | −127 | −131 | −103 | 141 | −48 | −87 | −101 | −172 | −197 | −49 |
| Net income | −131 | −123 | −120 | 130 | −59 | −88 | −102 | −177 | −200 | −50 |
| Diluted EPS (US$) | −1.27 | −1.17 | −1.14 | 1.16 | −0.53 | −0.60 | −0.62 | −0.80 | −0.63 | −0.14 |
| Diluted shares (millions) | 104 | 105 | 106 | 117 | 111 | 146 | 166 | 221 | 320 | 363 |
| Cash flow | ||||||||||
| Cash from operations | −176 | −185 | −149 | 114 | −143 | −87 | −89 | −162 | −179 | −68 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Free cash flow | −176 | −186 | −149 | 114 | −143 | −88 | −90 | −162 | −180 | −68 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 10 | 12 | 14 | 13 | 11 | 12 | 14 | 14 | 12 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 346 | 311 | 160 | 272 | 152 | 87 | 138 | 170 | 238 | 96 |
| Debt incl. finance leases | 101 | 252 | 250 | 249 | 12 | 0 | 49 | 100 | 100 | 54 |
| Total assets | 476 | 436 | 284 | 418 | 204 | 137 | 194 | 229 | 298 | 185 |
| Total liabilities | 318 | 368 | 310 | 301 | 47 | 23 | 77 | 136 | 152 | 77 |
| Shareholders' equity | 168 | 68 | −26 | 117 | 156 | 114 | 117 | 93 | 146 | 108 |
| Margins and ratios | ||||||||||
| Gross margin | 100.0% | 97.9% | 96.1% | 99.0% | 92.0% | 100.0% | 100.0% | 92.9% | 98.0% | 99.5% |
| Operating margin | −160.5% | −142.5% | −163.4% | 43.9% | −199.2% | −29,224.8% | −72,489.2% | −14,265.0% | −634.2% | −98.2% |
| Net margin | −165.8% | −134.1% | −190.7% | 40.4% | −244.1% | −29,449.0% | −73,341.0% | −14,710.9% | −644.8% | −101.1% |
| Free cash flow margin | −221.9% | −202.4% | −235.2% | 35.3% | −596.2% | −29,610.1% | −64,875.5% | −13,485.6% | −578.5% | −136.2% |
| Rule of 40 (growth + FCF margin) | −260.9% | −186.8% | −266.3% | 444.9% | −688.7% | −29,708.8% | −64,928.9% | −12,719.4% | 1,903.0% | −76.0% |
| Return on capital | — | — | −225.0% | 141.9% | −68.8% | −323.1% | −293.6% | −543.2% | — | −105.0% |
| Return on equity | −58.0% | −104.3% | −576.0% | 287.0% | −42.8% | −65.0% | −88.4% | −168.5% | −167.7% | −39.7% |
| Return on assets | −23.3% | −27.0% | −33.5% | 37.1% | −18.9% | −51.5% | −61.6% | −83.6% | −75.9% | −20.8% |
| Net debt to EBITDA | — | — | — | −0.2x | — | — | — | — | — | — |